ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Microbial Species and Antibiotic Resistance Identification in Patients Presenting to the Emergency Department With Three of Four Systemic Inflammatory Response Syndrome (SIRS) Criteria - is Rapid Identification Possible and Accurate?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01904188
Recruitment Status : Recruiting
First Posted : July 22, 2013
Last Update Posted : April 25, 2018
Sponsor:
Information provided by (Responsible Party):
Mary Hughes, Michigan State University

Brief Summary:
The aim of this project is to test the utility of the Gene-Z device as well as other rapid identification techniques that we have developed in the lab on clinically obtained bodily fluid samples taken from patients with suspected sepsis based on having three of four positive Systemic Inflammatory Response Syndrome markers, or having a known infection for which a specimen is being collected. Specimens will be collected by Sparrow Laboratories and McLaren Greater Lansing laboratories, processed and stored for analysis at a later date to determine if the microbial pathogens identified by current methods of culture, as well as pathogen susceptibility to antibiotics by culture results, can be identified by the GeneZ technology or other developed technology accurately, and more timely. It will not affect current patient care nor impact patient care, which will continue in the standard fashion today for sepsis. Results will be compared to standard culture results and antibiotic sensitivities.

Condition or disease Intervention/treatment
Sepsis Systemic Inflammatory Response Syndrome Device: Gene Z

Detailed Description:
Dramatic improvement in the timely and effective treatment of patients afflicted with sepsis can be achieved with the implementation of modern technologies for identification of offending microbial species and their innate genetic antibiotic treatment targets. Our collaborative team is planning to address this need using a Point-of-Care (POC) device equipped for identification of a bacterial species within 20 minutes of a routine Emergency Department laboratory blood draw or other specimen collection, followed by targeted analysis of its innate genetic antibiotic resistance elements within as little as 7 hours time. This revolutionary improvement in clinical management is critical for improving patient outcomes for a disease syndrome that is not only highly prevalent worldwide, consuming a massive amount of medical resources daily, but that only threatens to continue to worsen given current antibiotic stewardship practices. Early goal-directed therapy (EGDT) is the standard by which medical interventions are now shaped across fields in the modern clinical setting, ranging from trauma and neurosurgery to cardiology and infectious disease. Rapid and accurate diagnoses, paired with aggressive and effective intervention, are manifest to stemming the disease process as well as maintaining economically feasible care and improving long-term morbidity. The effort to apply EGDT to patients at high risk for systemic infection, sepsis, was initiated over a decade ago by Rivers and colleagues in the Emergency Department setting. Systematic approaches to early sepsis identification and intervention including broad-spectrum antibiotic coverage, and adequate fluid volume resuscitation have yielded definite improvements in patient outcomes and health care resource utilization. It has been recognized that one of the limiting factors in treatment of sepsis in the hospital setting is the timeliness of pathogen identification and implementation of appropriate antimicrobial therapy. The current "gold standard" of sepsis microbial identification is blood culture, which takes 3-5 days for a definitive species identification. Antimicrobial agent susceptibility for the given organism is generally garnered within this same timeframe. However, in the period it takes from specimen collection to culture results, empiric broad-spectrum antibiotic coverage, often involving multiple antibiotics, must be provided to ensure organism eradication. This proposal aims to use Point of Care (POC) testing, as described by our laboratory, to accurately identify pathogenic microorganisms in patients with suspected sepsis within 20 minutes of a laboratory blood draw or urine collection. The scope of our proposal is feasible in that 20 organisms account for 87% of microbial infections identified by culture-based techniques at Sparrow Hospital, representing the greater Lansing, Michigan area, and 50 microorganisms would account for virtually every microbial infectious species (Khalife, 2011, unpublished data). To date we have validated this approach with laboratory-processed samples of Escherichia coli and Staphylococcus aureus. POC testing will now be expanded to include additional microorganisms commonly encountered in sepsis patients. Secondarily, antimicrobial resistance genes will be scanned using a functional genomics approach with highly-parallel quantitative PCR as performed by our laboratory in a previous study exploring the microbiota of porcine gastrointestinal tract.

Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Clinical Microbial Species and Antibiotic Resistance Identification in Patients Presenting to the Emergency Department With Three of Four Systemic Inflammatory Response Syndrome (SIRS) Criteria - is Rapid Identification Possible and Accurate?
Study Start Date : June 2015
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
SIRS positive
Adult (> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection.
Device: Gene Z
The Gene Z device will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results



Primary Outcome Measures :
  1. Correlation of microbial identification with culture results from clinical laboratory [ Time Frame: 1 year ]
    Frozen microbial specimens will be transported to an off site laboratory for analysis with the GeneZ device, with investigators blinded to the final culture results of the specimen - positive or negative. Comparison will be made between final culture result and GeneZ identification of organism.


Secondary Outcome Measures :
  1. Microbial Resistance Gene Pattern [ Time Frame: 1 year ]
    Frozen specimens will be transported to an offsite laboratory where real time PCR will be used to identify microorganism resistance gene patterns of organisms identified by the GeneZ device. These will be compared to the antibiotic sensitivity results from the culture and sensitivity reports done in the clinical laboratory.


Biospecimen Retention:   None Retained
No specimens will be retained after analysis by study investigators. Prior to being sent to the laboratory they will be retained in frozen state until there is a large enough quantity to batch run specimens.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All adult patients who undergo evaluation for suspected sepsis who have peripheral blood cultures and urine samples obtained and patient characteristics recorded. In addition those that have an obvious infection without sepsis will be consented. Those that have other bodily fluids involved in addition will also be included.
Criteria

Inclusion Criteria:

Adult patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, and/or other bodily fluids collected for culture and sensitivity analysis.

Patients with other sources of infection with less than 3 of 4 SIRS criteria

Exclusion Criteria:

Pediatric patients Adult patients with less than 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01904188


Contacts
Contact: Mary J Hughes, DO 517-353-3211 hughesm@msu.edu
Contact: Brett Etchebarne, MD PhD 517-353-3211 madcow@msu.edu

Locations
United States, Michigan
Sparrow Health System Recruiting
Lansing, Michigan, United States, 48909
Contact: Walid Khalife, PhD    517-364-2170    walid.khalife@sparrow.org   
Sub-Investigator: Brett Etchebarne, MD/PhD         
Sub-Investigator: Walid Khalife, PhD         
Principal Investigator: Mary J Hughes, DO         
Sub-Investigator: Syed A Hashsham, PhD         
Sub-Investigator: James Tiedje, PhD         
Sponsors and Collaborators
Michigan State University
Investigators
Principal Investigator: Mary J Hughes, DO Michigan State University

Responsible Party: Mary Hughes, Professor of Emergency Medicine, Chair Department of Osteopathic Medical Specialties, Michigan State University
ClinicalTrials.gov Identifier: NCT01904188     History of Changes
Other Study ID Numbers: C13-033F
First Posted: July 22, 2013    Key Record Dates
Last Update Posted: April 25, 2018
Last Verified: August 2017

Keywords provided by Mary Hughes, Michigan State University:
microbial identification
antibiotic resistance
GeneZ and other techniques as developed
sepsis
Systemic Inflammatory Response Syndrome

Additional relevant MeSH terms:
Syndrome
Emergencies
Sepsis
Systemic Inflammatory Response Syndrome
Disease
Pathologic Processes
Disease Attributes
Infection
Inflammation
Shock
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents